Skip to main content
CRBP
NASDAQ Life Sciences

Corbus Pharmaceuticals Reports Q1 2026 Results, Confirms Key Clinical Milestones for CRB-701 & CRB-913

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$11.65
Mkt Cap
$195.811M
52W Low
$6.325
52W High
$20.56
52W Position info
84% above low
Off High info
43% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

CRBP sits 84% above its 52-week low of $6.325.

Summary

Corbus Pharmaceuticals reported Q1 2026 financials and provided key updates on its CRB-701 oncology program, including plans to start a registrational study this summer, and its CRB-913 obesity program, with topline Phase 1b data expected this summer.


Key Events · Product Development and Regulatory · CRBP

  • Q1 2026 Financial Results

    The company reported a net loss of $23.0 million for Q1 2026, an increase from $17.0 million in Q1 2025, primarily due to higher clinical development expenses.

  • Strong Cash Runway

    Corbus Pharmaceuticals holds $138.2 million in cash, cash equivalents, and investments as of March 31, 2026, which is expected to fund operations into 2028.

  • CRB-701 Oncology Program Advances

    The company confirmed broad alignment with the FDA on the registration path for CRB-701 in second-line HNSCC and plans to initiate a registrational study this summer. Updated monotherapy data will be presented at ASCO 2026.

  • CRB-913 Obesity Program Nears Data Readout

    Enrollment for the CANYON-1 Phase 1b clinical trial of CRB-913 has been completed, with topline 16-week data from 240 patients anticipated this summer.


Analysis · CRBP · Life Sciences

This 8-K provides Q1 2026 financial results, showing an increased net loss but a strong cash position expected to fund operations into 2028. More importantly for a clinical-stage biotech, it offers critical updates on its lead programs: CRB-701 (oncology) is on track to start a registrational study this summer with updated data at ASCO 2026, and CRB-913 (obesity) will report topline Phase 1b data this summer. These timelines provide clear near-term catalysts for investors.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 35.2% of the 2653 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRBP was trading at $11.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $195.8M. The 52-week trading range was $6.33 to $20.56. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRBP - Latest Insights

CRBP
Sep 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.08
Real-time Price: $3.10 info
Change: -$3.98 (-56%) info
Market Cap: $55.316M info
CRBP
Sep 14, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.26
Real-time Price: $3.10 info
Change: -$6.16 (-67%) info
Market Cap: $55.316M info
CRBP
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $8.91
Real-time Price: $3.10 info
Change: -$5.81 (-65%) info
Market Cap: $55.316M info
CRBP
Aug 07, 2026, 4:33 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $9.77
Real-time Price: $3.10 info
Change: -$6.67 (-68%) info
Market Cap: $55.316M info
CRBP
Aug 06, 2026, 4:35 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.65
Real-time Price: $3.10 info
Change: -$6.55 (-68%) info
Market Cap: $55.316M info